ABOUT

IHER’s mission is to bring together diverse collaborators across all communities, sectors, and scientific disciplines to generate evidence and innovate solutions that drive equity in health and health care. Our work is informed by four Core areas: health care delivery science, community engagement, data and research, and research workforce. Each Core encompasses multiple projects and initiatives led by our multidisciplinary team of nationally renowned health equity researchers. Our multi-pronged approach allows IHER to conduct clinical, translational, and health services science that transforms practice and policy in a comprehensive and enduring way.

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and twelve development-stage product candidates.

We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. We believe that our significant scale, flexible business model and extensive expertise uniquely position us to take advantage of the increasing innovation in the biopharmaceutical industry. We seek to create favorable outcomes for all parties and play an important role in providing capital to the biopharmaceutical ecosystem that supports innovation and positively impacts human health.

The Mount Sinai Royalty Pharma Alliance (MS-RP Alliance) for Health Equity Research in collaboration with Institute for Health Equity Research (IHER) was established through Royalty Pharma’s remarkable $20 million gift to support innovative, sustainable initiatives and policies to address systemic inequities in health care. The MS-RP Alliance Steering committee includes member of IHER and RP. One of the Alliance’s priorities is to build an infrastructure to exchange ideas and propel research collaboration.